MedTrace Logo

Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT07044349 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-06-30

No results posted yet for this study

Summary

This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules. Approximately 72 patients will be included in this study.

Conditions

Interventions

DRUG

Utidelone capsule 75mg/m2/d QD

75mg/m2/d, QD, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 40mg/m2/d BID

40mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 50mg/m2/d BID

50mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 35mg/m2/d BID

35mg/m2/d, BID, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

Sponsors & Collaborators

  • Beijing Biostar Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-30
Primary Completion
2027-03-31
Completion
2027-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07044349 on ClinicalTrials.gov